Submandibular gland botulinum neurotoxin A injection for predicting the outcome of submandibular duct relocation in drooling: a retrospective cohort study
Aim This study evaluated whether the effect of submandibular gland botulinum neurotoxin A (BoNT‐A) injection can predict the outcome of submandibular duct relocation with sublingual gland excision (SMDR) in children with drooling. Furthermore, we compared the effectiveness of both procedures. Method...
Gespeichert in:
| Veröffentlicht in: | Developmental medicine and child neurology 2019-11, Vol.61 (11), p.1323-1328 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1328 |
|---|---|
| container_issue | 11 |
| container_start_page | 1323 |
| container_title | Developmental medicine and child neurology |
| container_volume | 61 |
| creator | Kok, Saskia E Valenberg, Hans F J P Hulst, Karen Jongerius, Peter Erasmus, Corrie E Hoogen, Frank J A |
| description | Aim
This study evaluated whether the effect of submandibular gland botulinum neurotoxin A (BoNT‐A) injection can predict the outcome of submandibular duct relocation with sublingual gland excision (SMDR) in children with drooling. Furthermore, we compared the effectiveness of both procedures.
Method
A retrospective cohort study was performed in 42 children and adolescents (25 males, 17 females; mean [SD] age at BoNT‐A injection 11y [4], range 4–20y; mean [SD] age at SMDR 15y [4], range 7–23y) with cerebral palsy or another non‐progressive developmental disability who had undergone both BoNT‐A injection and SMDR for drooling. Main outcomes were the drooling quotient and the visual analogue scale (VAS) on drooling severity at 8 weeks and 32 weeks follow‐up.
Results
Failure or success of previous BoNT‐A injections had no influence on success of consecutive SMDR. Relative change in main outcomes showed no significant relation between BoNT‐A injection and SMDR for any follow‐up measurement. After 8 weeks, SMDR was more successful than BoNT‐A injection in diminishing VAS (VAS 80.0% vs 54.3%; drooling quotient 56.2% vs 51.0%). After 32 weeks, both drooling quotient (64.3% vs 29.5%) and VAS (75.7% vs 37.1%) showed significantly higher proportions of success for SMDR.
Interpretation
The effect of submandibular BoNT‐A injection does not predict subsequent SMDR success in drooling. Furthermore, SMDR has a larger and longer‐lasting positive effect on drooling than BoNT‐A injections.
What this paper adds
Submandibular botulinum neurotoxin A (BoNT‐A) injection effect does not predict submandibular duct relocation with sublingual gland excision outcome.
Submandibular duct relocation is more effective and more permanent than BoNT‐A injection.
Resumen
Inyección de neurotoxina botulínica A en la glándula submandibular para predecir el resultado de la reubicación del conducto submandibular en babeo: un estudio de cohorte retrospectivo
Objetivo
Este estudio evaluó si el efecto de la inyección de neurotoxina A botulínica submandibular (BoNT‐A) puede predecir el resultado de la reubicación del conducto submandibular con escisión de la glándula sublingual (SMDR) en niños con babeo. Además, comparamos la efectividad de ambos procedimientos.
Método
Se realizó un estudio de cohorte retrospectivo en 42 niños y adolescentes (25 varones, 17 mujeres; edad media [DE] en la inyección de BoNT‐A 11 años [4], rango 4‐20 años; edad media [SD] a SMDR 15 años [4] rango 7–23 años) con parálisis |
| doi_str_mv | 10.1111/dmcn.14199 |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1111_dmcn_14199</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>DMCN14199</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3589-c6c167ec6137003c77fd1f9f020e1a0f454b5e6e603fb080ea86679276bd6f053</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EoqWw4QOQ10gpduI4CbuqPKUCC2AdOX60rpI4cmygv8LX4jaAxAZvxiMfH81cAE4xmuJwLkTD2ykmuCj2wBgTWkR5Rop9MEYIxxGmcTwCR32_RgglNCWHYJSgPCWU5GPw-eyrhrVCV75mFi7rcIeVcb7WrW9gK701znzoFs6gbteSO21aqIyFnZVCh7ZdQreS0HjHTROqgv0fpfDcQStrw9nub1AJa0zwLy8hCy_Omr7bit8k5GZlrIO982JzDA4Uq3t58l0n4PXm-mV-Fy2ebu_ns0XEkzQvIk45ppnkFCdZWJBnmRJYFQrFSGKGFElJlUoqKUpUhXIkWU5pVsQZrQRVKE0m4Hzw8jBIb6UqO6sbZjclRuU24HIbcLkLOMBnA9yFJaX4RX8SDQAegHddy80_qvLqYf44SL8ACHyKgg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Submandibular gland botulinum neurotoxin A injection for predicting the outcome of submandibular duct relocation in drooling: a retrospective cohort study</title><source>MEDLINE</source><source>Wiley Online Library</source><creator>Kok, Saskia E ; Valenberg, Hans F J P ; Hulst, Karen ; Jongerius, Peter ; Erasmus, Corrie E ; Hoogen, Frank J A</creator><creatorcontrib>Kok, Saskia E ; Valenberg, Hans F J P ; Hulst, Karen ; Jongerius, Peter ; Erasmus, Corrie E ; Hoogen, Frank J A</creatorcontrib><description>Aim
This study evaluated whether the effect of submandibular gland botulinum neurotoxin A (BoNT‐A) injection can predict the outcome of submandibular duct relocation with sublingual gland excision (SMDR) in children with drooling. Furthermore, we compared the effectiveness of both procedures.
Method
A retrospective cohort study was performed in 42 children and adolescents (25 males, 17 females; mean [SD] age at BoNT‐A injection 11y [4], range 4–20y; mean [SD] age at SMDR 15y [4], range 7–23y) with cerebral palsy or another non‐progressive developmental disability who had undergone both BoNT‐A injection and SMDR for drooling. Main outcomes were the drooling quotient and the visual analogue scale (VAS) on drooling severity at 8 weeks and 32 weeks follow‐up.
Results
Failure or success of previous BoNT‐A injections had no influence on success of consecutive SMDR. Relative change in main outcomes showed no significant relation between BoNT‐A injection and SMDR for any follow‐up measurement. After 8 weeks, SMDR was more successful than BoNT‐A injection in diminishing VAS (VAS 80.0% vs 54.3%; drooling quotient 56.2% vs 51.0%). After 32 weeks, both drooling quotient (64.3% vs 29.5%) and VAS (75.7% vs 37.1%) showed significantly higher proportions of success for SMDR.
Interpretation
The effect of submandibular BoNT‐A injection does not predict subsequent SMDR success in drooling. Furthermore, SMDR has a larger and longer‐lasting positive effect on drooling than BoNT‐A injections.
What this paper adds
Submandibular botulinum neurotoxin A (BoNT‐A) injection effect does not predict submandibular duct relocation with sublingual gland excision outcome.
Submandibular duct relocation is more effective and more permanent than BoNT‐A injection.
Resumen
Inyección de neurotoxina botulínica A en la glándula submandibular para predecir el resultado de la reubicación del conducto submandibular en babeo: un estudio de cohorte retrospectivo
Objetivo
Este estudio evaluó si el efecto de la inyección de neurotoxina A botulínica submandibular (BoNT‐A) puede predecir el resultado de la reubicación del conducto submandibular con escisión de la glándula sublingual (SMDR) en niños con babeo. Además, comparamos la efectividad de ambos procedimientos.
Método
Se realizó un estudio de cohorte retrospectivo en 42 niños y adolescentes (25 varones, 17 mujeres; edad media [DE] en la inyección de BoNT‐A 11 años [4], rango 4‐20 años; edad media [SD] a SMDR 15 años [4] rango 7–23 años) con parálisis cerebral u otra discapacidad del desarrollo no progresiva que se haya sometido a una inyección de BoNT‐A y SMDR para babear. Los resultados principales fueron el cociente de babeo y la escala analógica visual (VAS) en la severidad del babeo a las 8 semanas y 32 semanas de seguimiento.
Resultados
El fracaso o el éxito de las inyecciones anteriores de BoNT‐A no tuvo influencia en el éxito de la SMDR consecutiva. El cambio relativo en los resultados principales no mostró una relación significativa entre la inyección de BoNT‐A y SMDR para cualquier medición de seguimiento. Después de 8 semanas, SMDR fue más exitoso que la inyección de BoNT‐A en la VAS disminuida (VAS 80,0% vs 54,3%; cociente de babeo 56,2% vs 51,0%). Después de 32 semanas, tanto el cociente de babeo (64,3% vs 29,5%) como el VAS (75,7% vs 37,1%) mostraron proporciones significativamente más altas de éxito para SMDR.
Interpretación
El efecto de la inyección submandibular de BoNT‐A no predice el éxito posterior de SMDR en el babeo. Además, el SMDR tiene un efecto positivo mayor y más duradero en el babeo que las inyecciones de BoNT‐A.
Injeção de neurotoxina botulínica na glândula submandibular para predição do resultado da relocacão do ducto submandibular na sialorréia: um estudo de coorte retrospectivo
Objetivo
Este estudo avaliou se o efeito da neurotoxina botulínica A (NTBo‐A) na glândula submandibular pode predizer o resultado da relocação do ducto submandibular com excisão sublingual da glândula (RDSM) em crianças com sialorréia. Ainda, comparamos a efetividade de ambos os procedimentos.
Método
Um estudo de coorte retrospectivo foi realizado em 42 crianças e adolescentes (25 do sexo masculino, 17 do sexo feminino; idade média [DP] no momento da injeção de NTBo‐A 11a[4], variação de 4–20a; idade média [DP] no momento da RDSM 15a [4], variação de 7–23a) com paralisia cerebral ou outra desordem não‐progressiva do desenvolvimento que passaram por injeção de NTBo‐A e RDSM para sialorréia. Os principais desfechos foram o quociente de sialorréia e a escala visual análoga (EVA) sobre a severidade da sialorréia no acompanhamento de 8 e 32 semanas.
Resultados
A falha ou sucesso da NTBo‐A prévia não teve influência no sucesso da RDSM consecutiva. A mudança relativa nos principais desfechos não mostrou nenhuma relação significativa entre a injeção de NTBo‐A e a RDSM para nenhuma das medidas no acompanhamento. Após 8 semanas, a RDSM foi mais bem sucedida do que a NTBo‐A na redução da EVA (EVA 80,0% vs 54,3%; quociente de sialorréia 56,2% vs 51,0%). Após 32 semanas, tanto o quociente de sialorréia (64,3% vs 29,5%) quanto a EVA (75,7% vs 37,1%) mostram proporções significativamente mais altas de sucesso para a RDSM.
Interpretação
O efeito da injeção submandibular de NTBo‐A não prediz o sucesso da RDSM subsequente na sialorréia. Ainda, a RDSM tem efeito maior e mais duradouro na sialorréia do que injeções de NTBo‐A.
What this paper adds
Submandibular botulinum neurotoxin A (BoNT‐A) injection effect does not predict submandibular duct relocation with sublingual gland excision outcome.
Submandibular duct relocation is more effective and more permanent than BoNT‐A injection.
This article's has been translated into Spanish and Portuguese.
Follow the links from the to view the translations.</description><identifier>ISSN: 0012-1622</identifier><identifier>EISSN: 1469-8749</identifier><identifier>DOI: 10.1111/dmcn.14199</identifier><identifier>PMID: 30854648</identifier><language>eng</language><publisher>England</publisher><subject>Acetylcholine Release Inhibitors - administration & dosage ; Adolescent ; Adult ; Botulinum Toxins, Type A - administration & dosage ; Child ; Female ; Humans ; Injections ; Male ; Prognosis ; Retrospective Studies ; Sialorrhea - complications ; Sialorrhea - diagnosis ; Sialorrhea - drug therapy ; Sialorrhea - surgery ; Submandibular Gland - drug effects ; Submandibular Gland - surgery ; Treatment Outcome ; Young Adult</subject><ispartof>Developmental medicine and child neurology, 2019-11, Vol.61 (11), p.1323-1328</ispartof><rights>2019 Mac Keith Press</rights><rights>2019 Mac Keith Press.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3589-c6c167ec6137003c77fd1f9f020e1a0f454b5e6e603fb080ea86679276bd6f053</citedby><cites>FETCH-LOGICAL-c3589-c6c167ec6137003c77fd1f9f020e1a0f454b5e6e603fb080ea86679276bd6f053</cites><orcidid>0000-0001-9456-3450 ; 0000-0003-4773-5461</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fdmcn.14199$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fdmcn.14199$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30854648$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kok, Saskia E</creatorcontrib><creatorcontrib>Valenberg, Hans F J P</creatorcontrib><creatorcontrib>Hulst, Karen</creatorcontrib><creatorcontrib>Jongerius, Peter</creatorcontrib><creatorcontrib>Erasmus, Corrie E</creatorcontrib><creatorcontrib>Hoogen, Frank J A</creatorcontrib><title>Submandibular gland botulinum neurotoxin A injection for predicting the outcome of submandibular duct relocation in drooling: a retrospective cohort study</title><title>Developmental medicine and child neurology</title><addtitle>Dev Med Child Neurol</addtitle><description>Aim
This study evaluated whether the effect of submandibular gland botulinum neurotoxin A (BoNT‐A) injection can predict the outcome of submandibular duct relocation with sublingual gland excision (SMDR) in children with drooling. Furthermore, we compared the effectiveness of both procedures.
Method
A retrospective cohort study was performed in 42 children and adolescents (25 males, 17 females; mean [SD] age at BoNT‐A injection 11y [4], range 4–20y; mean [SD] age at SMDR 15y [4], range 7–23y) with cerebral palsy or another non‐progressive developmental disability who had undergone both BoNT‐A injection and SMDR for drooling. Main outcomes were the drooling quotient and the visual analogue scale (VAS) on drooling severity at 8 weeks and 32 weeks follow‐up.
Results
Failure or success of previous BoNT‐A injections had no influence on success of consecutive SMDR. Relative change in main outcomes showed no significant relation between BoNT‐A injection and SMDR for any follow‐up measurement. After 8 weeks, SMDR was more successful than BoNT‐A injection in diminishing VAS (VAS 80.0% vs 54.3%; drooling quotient 56.2% vs 51.0%). After 32 weeks, both drooling quotient (64.3% vs 29.5%) and VAS (75.7% vs 37.1%) showed significantly higher proportions of success for SMDR.
Interpretation
The effect of submandibular BoNT‐A injection does not predict subsequent SMDR success in drooling. Furthermore, SMDR has a larger and longer‐lasting positive effect on drooling than BoNT‐A injections.
What this paper adds
Submandibular botulinum neurotoxin A (BoNT‐A) injection effect does not predict submandibular duct relocation with sublingual gland excision outcome.
Submandibular duct relocation is more effective and more permanent than BoNT‐A injection.
Resumen
Inyección de neurotoxina botulínica A en la glándula submandibular para predecir el resultado de la reubicación del conducto submandibular en babeo: un estudio de cohorte retrospectivo
Objetivo
Este estudio evaluó si el efecto de la inyección de neurotoxina A botulínica submandibular (BoNT‐A) puede predecir el resultado de la reubicación del conducto submandibular con escisión de la glándula sublingual (SMDR) en niños con babeo. Además, comparamos la efectividad de ambos procedimientos.
Método
Se realizó un estudio de cohorte retrospectivo en 42 niños y adolescentes (25 varones, 17 mujeres; edad media [DE] en la inyección de BoNT‐A 11 años [4], rango 4‐20 años; edad media [SD] a SMDR 15 años [4] rango 7–23 años) con parálisis cerebral u otra discapacidad del desarrollo no progresiva que se haya sometido a una inyección de BoNT‐A y SMDR para babear. Los resultados principales fueron el cociente de babeo y la escala analógica visual (VAS) en la severidad del babeo a las 8 semanas y 32 semanas de seguimiento.
Resultados
El fracaso o el éxito de las inyecciones anteriores de BoNT‐A no tuvo influencia en el éxito de la SMDR consecutiva. El cambio relativo en los resultados principales no mostró una relación significativa entre la inyección de BoNT‐A y SMDR para cualquier medición de seguimiento. Después de 8 semanas, SMDR fue más exitoso que la inyección de BoNT‐A en la VAS disminuida (VAS 80,0% vs 54,3%; cociente de babeo 56,2% vs 51,0%). Después de 32 semanas, tanto el cociente de babeo (64,3% vs 29,5%) como el VAS (75,7% vs 37,1%) mostraron proporciones significativamente más altas de éxito para SMDR.
Interpretación
El efecto de la inyección submandibular de BoNT‐A no predice el éxito posterior de SMDR en el babeo. Además, el SMDR tiene un efecto positivo mayor y más duradero en el babeo que las inyecciones de BoNT‐A.
Injeção de neurotoxina botulínica na glândula submandibular para predição do resultado da relocacão do ducto submandibular na sialorréia: um estudo de coorte retrospectivo
Objetivo
Este estudo avaliou se o efeito da neurotoxina botulínica A (NTBo‐A) na glândula submandibular pode predizer o resultado da relocação do ducto submandibular com excisão sublingual da glândula (RDSM) em crianças com sialorréia. Ainda, comparamos a efetividade de ambos os procedimentos.
Método
Um estudo de coorte retrospectivo foi realizado em 42 crianças e adolescentes (25 do sexo masculino, 17 do sexo feminino; idade média [DP] no momento da injeção de NTBo‐A 11a[4], variação de 4–20a; idade média [DP] no momento da RDSM 15a [4], variação de 7–23a) com paralisia cerebral ou outra desordem não‐progressiva do desenvolvimento que passaram por injeção de NTBo‐A e RDSM para sialorréia. Os principais desfechos foram o quociente de sialorréia e a escala visual análoga (EVA) sobre a severidade da sialorréia no acompanhamento de 8 e 32 semanas.
Resultados
A falha ou sucesso da NTBo‐A prévia não teve influência no sucesso da RDSM consecutiva. A mudança relativa nos principais desfechos não mostrou nenhuma relação significativa entre a injeção de NTBo‐A e a RDSM para nenhuma das medidas no acompanhamento. Após 8 semanas, a RDSM foi mais bem sucedida do que a NTBo‐A na redução da EVA (EVA 80,0% vs 54,3%; quociente de sialorréia 56,2% vs 51,0%). Após 32 semanas, tanto o quociente de sialorréia (64,3% vs 29,5%) quanto a EVA (75,7% vs 37,1%) mostram proporções significativamente mais altas de sucesso para a RDSM.
Interpretação
O efeito da injeção submandibular de NTBo‐A não prediz o sucesso da RDSM subsequente na sialorréia. Ainda, a RDSM tem efeito maior e mais duradouro na sialorréia do que injeções de NTBo‐A.
What this paper adds
Submandibular botulinum neurotoxin A (BoNT‐A) injection effect does not predict submandibular duct relocation with sublingual gland excision outcome.
Submandibular duct relocation is more effective and more permanent than BoNT‐A injection.
This article's has been translated into Spanish and Portuguese.
Follow the links from the to view the translations.</description><subject>Acetylcholine Release Inhibitors - administration & dosage</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Botulinum Toxins, Type A - administration & dosage</subject><subject>Child</subject><subject>Female</subject><subject>Humans</subject><subject>Injections</subject><subject>Male</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Sialorrhea - complications</subject><subject>Sialorrhea - diagnosis</subject><subject>Sialorrhea - drug therapy</subject><subject>Sialorrhea - surgery</subject><subject>Submandibular Gland - drug effects</subject><subject>Submandibular Gland - surgery</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0012-1622</issn><issn>1469-8749</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOwzAQRS0EoqWw4QOQ10gpduI4CbuqPKUCC2AdOX60rpI4cmygv8LX4jaAxAZvxiMfH81cAE4xmuJwLkTD2ykmuCj2wBgTWkR5Rop9MEYIxxGmcTwCR32_RgglNCWHYJSgPCWU5GPw-eyrhrVCV75mFi7rcIeVcb7WrW9gK701znzoFs6gbteSO21aqIyFnZVCh7ZdQreS0HjHTROqgv0fpfDcQStrw9nub1AJa0zwLy8hCy_Omr7bit8k5GZlrIO982JzDA4Uq3t58l0n4PXm-mV-Fy2ebu_ns0XEkzQvIk45ppnkFCdZWJBnmRJYFQrFSGKGFElJlUoqKUpUhXIkWU5pVsQZrQRVKE0m4Hzw8jBIb6UqO6sbZjclRuU24HIbcLkLOMBnA9yFJaX4RX8SDQAegHddy80_qvLqYf44SL8ACHyKgg</recordid><startdate>201911</startdate><enddate>201911</enddate><creator>Kok, Saskia E</creator><creator>Valenberg, Hans F J P</creator><creator>Hulst, Karen</creator><creator>Jongerius, Peter</creator><creator>Erasmus, Corrie E</creator><creator>Hoogen, Frank J A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0001-9456-3450</orcidid><orcidid>https://orcid.org/0000-0003-4773-5461</orcidid></search><sort><creationdate>201911</creationdate><title>Submandibular gland botulinum neurotoxin A injection for predicting the outcome of submandibular duct relocation in drooling: a retrospective cohort study</title><author>Kok, Saskia E ; Valenberg, Hans F J P ; Hulst, Karen ; Jongerius, Peter ; Erasmus, Corrie E ; Hoogen, Frank J A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3589-c6c167ec6137003c77fd1f9f020e1a0f454b5e6e603fb080ea86679276bd6f053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acetylcholine Release Inhibitors - administration & dosage</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Botulinum Toxins, Type A - administration & dosage</topic><topic>Child</topic><topic>Female</topic><topic>Humans</topic><topic>Injections</topic><topic>Male</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Sialorrhea - complications</topic><topic>Sialorrhea - diagnosis</topic><topic>Sialorrhea - drug therapy</topic><topic>Sialorrhea - surgery</topic><topic>Submandibular Gland - drug effects</topic><topic>Submandibular Gland - surgery</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kok, Saskia E</creatorcontrib><creatorcontrib>Valenberg, Hans F J P</creatorcontrib><creatorcontrib>Hulst, Karen</creatorcontrib><creatorcontrib>Jongerius, Peter</creatorcontrib><creatorcontrib>Erasmus, Corrie E</creatorcontrib><creatorcontrib>Hoogen, Frank J A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Developmental medicine and child neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kok, Saskia E</au><au>Valenberg, Hans F J P</au><au>Hulst, Karen</au><au>Jongerius, Peter</au><au>Erasmus, Corrie E</au><au>Hoogen, Frank J A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Submandibular gland botulinum neurotoxin A injection for predicting the outcome of submandibular duct relocation in drooling: a retrospective cohort study</atitle><jtitle>Developmental medicine and child neurology</jtitle><addtitle>Dev Med Child Neurol</addtitle><date>2019-11</date><risdate>2019</risdate><volume>61</volume><issue>11</issue><spage>1323</spage><epage>1328</epage><pages>1323-1328</pages><issn>0012-1622</issn><eissn>1469-8749</eissn><abstract>Aim
This study evaluated whether the effect of submandibular gland botulinum neurotoxin A (BoNT‐A) injection can predict the outcome of submandibular duct relocation with sublingual gland excision (SMDR) in children with drooling. Furthermore, we compared the effectiveness of both procedures.
Method
A retrospective cohort study was performed in 42 children and adolescents (25 males, 17 females; mean [SD] age at BoNT‐A injection 11y [4], range 4–20y; mean [SD] age at SMDR 15y [4], range 7–23y) with cerebral palsy or another non‐progressive developmental disability who had undergone both BoNT‐A injection and SMDR for drooling. Main outcomes were the drooling quotient and the visual analogue scale (VAS) on drooling severity at 8 weeks and 32 weeks follow‐up.
Results
Failure or success of previous BoNT‐A injections had no influence on success of consecutive SMDR. Relative change in main outcomes showed no significant relation between BoNT‐A injection and SMDR for any follow‐up measurement. After 8 weeks, SMDR was more successful than BoNT‐A injection in diminishing VAS (VAS 80.0% vs 54.3%; drooling quotient 56.2% vs 51.0%). After 32 weeks, both drooling quotient (64.3% vs 29.5%) and VAS (75.7% vs 37.1%) showed significantly higher proportions of success for SMDR.
Interpretation
The effect of submandibular BoNT‐A injection does not predict subsequent SMDR success in drooling. Furthermore, SMDR has a larger and longer‐lasting positive effect on drooling than BoNT‐A injections.
What this paper adds
Submandibular botulinum neurotoxin A (BoNT‐A) injection effect does not predict submandibular duct relocation with sublingual gland excision outcome.
Submandibular duct relocation is more effective and more permanent than BoNT‐A injection.
Resumen
Inyección de neurotoxina botulínica A en la glándula submandibular para predecir el resultado de la reubicación del conducto submandibular en babeo: un estudio de cohorte retrospectivo
Objetivo
Este estudio evaluó si el efecto de la inyección de neurotoxina A botulínica submandibular (BoNT‐A) puede predecir el resultado de la reubicación del conducto submandibular con escisión de la glándula sublingual (SMDR) en niños con babeo. Además, comparamos la efectividad de ambos procedimientos.
Método
Se realizó un estudio de cohorte retrospectivo en 42 niños y adolescentes (25 varones, 17 mujeres; edad media [DE] en la inyección de BoNT‐A 11 años [4], rango 4‐20 años; edad media [SD] a SMDR 15 años [4] rango 7–23 años) con parálisis cerebral u otra discapacidad del desarrollo no progresiva que se haya sometido a una inyección de BoNT‐A y SMDR para babear. Los resultados principales fueron el cociente de babeo y la escala analógica visual (VAS) en la severidad del babeo a las 8 semanas y 32 semanas de seguimiento.
Resultados
El fracaso o el éxito de las inyecciones anteriores de BoNT‐A no tuvo influencia en el éxito de la SMDR consecutiva. El cambio relativo en los resultados principales no mostró una relación significativa entre la inyección de BoNT‐A y SMDR para cualquier medición de seguimiento. Después de 8 semanas, SMDR fue más exitoso que la inyección de BoNT‐A en la VAS disminuida (VAS 80,0% vs 54,3%; cociente de babeo 56,2% vs 51,0%). Después de 32 semanas, tanto el cociente de babeo (64,3% vs 29,5%) como el VAS (75,7% vs 37,1%) mostraron proporciones significativamente más altas de éxito para SMDR.
Interpretación
El efecto de la inyección submandibular de BoNT‐A no predice el éxito posterior de SMDR en el babeo. Además, el SMDR tiene un efecto positivo mayor y más duradero en el babeo que las inyecciones de BoNT‐A.
Injeção de neurotoxina botulínica na glândula submandibular para predição do resultado da relocacão do ducto submandibular na sialorréia: um estudo de coorte retrospectivo
Objetivo
Este estudo avaliou se o efeito da neurotoxina botulínica A (NTBo‐A) na glândula submandibular pode predizer o resultado da relocação do ducto submandibular com excisão sublingual da glândula (RDSM) em crianças com sialorréia. Ainda, comparamos a efetividade de ambos os procedimentos.
Método
Um estudo de coorte retrospectivo foi realizado em 42 crianças e adolescentes (25 do sexo masculino, 17 do sexo feminino; idade média [DP] no momento da injeção de NTBo‐A 11a[4], variação de 4–20a; idade média [DP] no momento da RDSM 15a [4], variação de 7–23a) com paralisia cerebral ou outra desordem não‐progressiva do desenvolvimento que passaram por injeção de NTBo‐A e RDSM para sialorréia. Os principais desfechos foram o quociente de sialorréia e a escala visual análoga (EVA) sobre a severidade da sialorréia no acompanhamento de 8 e 32 semanas.
Resultados
A falha ou sucesso da NTBo‐A prévia não teve influência no sucesso da RDSM consecutiva. A mudança relativa nos principais desfechos não mostrou nenhuma relação significativa entre a injeção de NTBo‐A e a RDSM para nenhuma das medidas no acompanhamento. Após 8 semanas, a RDSM foi mais bem sucedida do que a NTBo‐A na redução da EVA (EVA 80,0% vs 54,3%; quociente de sialorréia 56,2% vs 51,0%). Após 32 semanas, tanto o quociente de sialorréia (64,3% vs 29,5%) quanto a EVA (75,7% vs 37,1%) mostram proporções significativamente mais altas de sucesso para a RDSM.
Interpretação
O efeito da injeção submandibular de NTBo‐A não prediz o sucesso da RDSM subsequente na sialorréia. Ainda, a RDSM tem efeito maior e mais duradouro na sialorréia do que injeções de NTBo‐A.
What this paper adds
Submandibular botulinum neurotoxin A (BoNT‐A) injection effect does not predict submandibular duct relocation with sublingual gland excision outcome.
Submandibular duct relocation is more effective and more permanent than BoNT‐A injection.
This article's has been translated into Spanish and Portuguese.
Follow the links from the to view the translations.</abstract><cop>England</cop><pmid>30854648</pmid><doi>10.1111/dmcn.14199</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-9456-3450</orcidid><orcidid>https://orcid.org/0000-0003-4773-5461</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-1622 |
| ispartof | Developmental medicine and child neurology, 2019-11, Vol.61 (11), p.1323-1328 |
| issn | 0012-1622 1469-8749 |
| language | eng |
| recordid | cdi_crossref_primary_10_1111_dmcn_14199 |
| source | MEDLINE; Wiley Online Library |
| subjects | Acetylcholine Release Inhibitors - administration & dosage Adolescent Adult Botulinum Toxins, Type A - administration & dosage Child Female Humans Injections Male Prognosis Retrospective Studies Sialorrhea - complications Sialorrhea - diagnosis Sialorrhea - drug therapy Sialorrhea - surgery Submandibular Gland - drug effects Submandibular Gland - surgery Treatment Outcome Young Adult |
| title | Submandibular gland botulinum neurotoxin A injection for predicting the outcome of submandibular duct relocation in drooling: a retrospective cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T18%3A59%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Submandibular%20gland%20botulinum%20neurotoxin%20A%20injection%20for%20predicting%20the%20outcome%20of%20submandibular%20duct%20relocation%20in%20drooling:%20a%20retrospective%20cohort%20study&rft.jtitle=Developmental%20medicine%20and%20child%20neurology&rft.au=Kok,%20Saskia%20E&rft.date=2019-11&rft.volume=61&rft.issue=11&rft.spage=1323&rft.epage=1328&rft.pages=1323-1328&rft.issn=0012-1622&rft.eissn=1469-8749&rft_id=info:doi/10.1111/dmcn.14199&rft_dat=%3Cwiley_cross%3EDMCN14199%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/30854648&rfr_iscdi=true |